Non-peptide compound reference

NAD+

Also known as Nicotinamide adenine dinucleotide · Oxidized NAD

A ubiquitous cellular redox cofactor rather than a peptide. NAD biology is well established, but direct parenteral NAD+ for wellness has very limited clinical-outcomes evidence.

  • Longevity & mitochondria
Early human evidence2 referencesEducational use

Dosing literacy

Dosing & scaling, explained

The in-app 50–100 mg injection presets are source-library conventions. The cited human IV pilot used a different route, amount, and six-hour infusion. This is educational source context—not a protocol or recommendation.

Scaling framework

How sourced amounts are organized

  1. Starting pointNot clinically established
    No validated titration window

    There is no regulator-approved starting dose for this research use. A low-looking number is not automatically safe.

  2. Recorded preset50–100 mg per administration
    Calculator library reference

    This is the range represented in the in-app protocol library. It describes the source record; it does not validate the regimen.

  3. Higher exposureNo validated bolus ceiling
    Risk and uncertainty increase

    Higher exposure is not established as more effective. Human pharmacokinetic and long-term safety data may be absent.

Route and infusion rate are central to interpretation. A slow IV infusion cannot validate a subcutaneous or intramuscular preset.

Schedule literacy

Patterns described in source material

  • Every 2–3 days in recorded presets

    The cadence represented by the recorded calculator presets.

  • 750 mg over 6 hours in one IV PK pilot

    Published experiments may use a different route, formulation, timing, or population and should not be treated as interchangeable.

  • No universal schedule

    No single schedule has been validated across products or research contexts.

Clinical context
  • 750 mg total · 6-hour IV infusionHuman metabolome pilotn=8 active participants

The pilot characterized metabolism and tolerability; it did not establish a therapeutic dose or outcome.

Research best practices

Storage, handling and interpretation

Lyophilized material

Keep cold, dry, and protected from light according to the manufacturer certificate or validated lab SOP.

After reconstitution

Use sterile technique, refrigerate as validated, and avoid repeated freeze–thaw cycles.

Traceability

Record lot, concentration, preparation date, and the identity/purity documentation used by the lab.

Research orientation

What researchers are exploring

These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.

  • 01

    Cellular redox

    NAD+/NADH couples carry electrons in core metabolic pathways.

  • 02

    Enzyme signaling

    NAD+ is consumed by sirtuins, PARPs, and other signaling enzymes.

  • 03

    Aging biology

    Precursor strategies aim to change NAD-related metabolites, with mixed functional outcomes.

  • 04

    Parenteral pharmacokinetics

    A small IV pilot measured plasma and urinary metabolites during a six-hour infusion.

Evidence map

What the current evidence can support

Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.

  • Human

    Small IV pharmacokinetic pilot

    Eight participants received 750 mg NAD+ over six hours; the study measured metabolite handling, not clinical efficacy.

  • Review

    Precursor evidence is not direct NAD+ evidence

    Human NR and NMN trials cannot be automatically generalized to injected NAD+.

  • Review

    Clinical outcomes remain inconclusive

    Reviews find biochemical target engagement more consistently than meaningful health outcomes.

Recorded protocol library

Amounts recorded for NAD+

These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.

  • 01

    Lower recorded

    50 mg

    Sign in for schedule, duration and source context.

  • 02

    Typical Dose Range · upper endpoint

    250 mg

    Sign in for schedule, duration and source context.

  • 03

    More Intensive Therapy · lower endpoint

    500 mg

    Sign in for schedule, duration and source context.

Technical reference

Identity, limitations and unknowns

Molecular profile

Class
Pyridine dinucleotide cofactor
Approx. MW
663.43 Da
Origin / design
Endogenous redox and enzyme cosubstrate present in all cells

Important limitations

  • NAD+, NADH, NR, NMN, niacin, and nicotinamide are related but non-interchangeable interventions.
  • Direct IV/IM NAD+ lacks large randomized outcomes trials for anti-aging or wellness claims.
  • A calculator preset is a recorded research convention, not a recommendation or evidence of clinical benefit.
  • Identity, purity, sterility, and stability can vary substantially outside regulated manufacturing.
  • Route, formulation, and population can make results from one study inapplicable to another use.

Curated sources

2 curated references

  1. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+Frontiers in Aging Neuroscience · 2019 · Human
  2. NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic reviewSystematic review · 2026 · Review

Related profiles